David Solit, MD
Enriched profileDirector of Developmental Therapeutics, Geoffrey Beene Chair for Cancer Research, Co-Director of the Marie-Josée & Henry R. Kravis Center for Molecular Oncology · Memorial Sloan Kettering Cancer Center
David Solit is Director of Developmental Therapeutics, Geoffrey Beene Chair for Cancer Research, Co-Director of the Marie-Josée & Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 1,856 publications with 82,661 citations (h-index 141); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the FindMyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 25 Oct 2026
David Solit, MD, is Director of Developmental Therapeutics, Geoffrey Beene Chair for Cancer Research, Co-Director of the Marie-Josée & Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. The public record shows 1,856 publications with 82,661 citations (h-index 141), centered on Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Bladder and Urothelial Cancer Treatments. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 5 companies, 14 NIH-funded awards (2008–2026).
- Most recent indexed publication: 2026 · Cancer discovery
- Top research focus: Cancer Genomics and Diagnostics
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 83 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 395.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 25 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Genomic Profiling in Cancer Patients
Sponsor: Memorial Sloan Kettering Cancer Center
- Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Sponsor: National Cancer Institute (NCI)
- Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 25 Oct 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments$18,940openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20248 payments$28,156openpaymentsdata.cms.gov ↗
- Vividion Therapeutics Inc.Program year20231 payment$51,566openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
71.6%Cytochrome P450 17A1 Inhibitor33.3%Abiraterone Acetate100%Part D<11 patientsAnti-androgens30.9%Nubeqa100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
28.4%Corticosteroid28.4%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 25 Oct 2026
14 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:
- HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancer
Sloan-Kettering Inst Can Research
FY2026$715,002R01CA309345 - HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma
Sloan-Kettering Inst Can Research
FY2026$594,012R01CA288692
Congress activity
Updated 25 Oct 2026
278 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 2498: OncoKB™, MSK’s precision oncology knowledge base: 2025 updates
AACR Annual Meeting
AACR2026Co-author - Abstract 3093: SLC25A28 is a synthetic lethal target in nucleotide excision repair-deficient cancer
AACR Annual Meeting
AACR2026Co-author - Abstract 4036: Deciphering regulatory drivers of lineage plasticity and resistance to antibody-drug conjugates in urothelial bladder cancer
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 25 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer.
Research square
Article2026 - Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.
Clinical cancer research
Article2026 - Target Antigen Identification for Antibody Drug Conjugate Therapy in Biliary Tract Cancer.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01Tumor mutational load predicts survival after immunotherapy across multiple cancer typesArticle4,063 citations2019
- 02
- 03OncoKB: A Precision Oncology Knowledge BaseArticle2,697 citations2017
- 04mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktArticle2,554 citations2006
- 05AACR Project GENIE: Powering Precision Medicine through an International ConsortiumArticle1,947 citations2017
Network
Updated 25 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 25 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/david-solit-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
mskcc.org/news/dr-solit-actionable-cancer-genomes-msk-science-spotlight
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 25 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Pennsylvania School of Medicine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- Member
American Society for Clinical Investigation
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Kimmel Scholar
Sidney Kimmel Foundation for Cancer Research
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Career Development Award
American Society of Clinical Oncology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Young Investigator Award
American Society of Clinical
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Doris Duke Translational Award
Doris Duke Foundation
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Clinical Scholars Research Fellow
National Institutes of Health
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- Faculty
Weill Cornell Graduate School of Medical Sciences
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →gradschool.weillcornell.org ↗ - verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →voicesinbioethics.podcasts.library.columbia.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center